Q-omics provides the consensus-scored NDUFS5P3 profile across patient tissues and cancer cell-line models. NDUFS5P3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, NDUFS5P3 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, NDUFS5P3 RNA expression shows 6,384 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight STAD, KIRC, and BRCA as cancer lineages where NDUFS5P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFS5P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFS5P3 survival associations across molecular data types. NDUFS5P3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFS5P3 RNA expression–survival associations across cancer types. High NDUFS5P3 expression shows unfavorable associations in ESCA, MESO and UCS, but favorable associations in STAD, BLCA and SKCM. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for NDUFS5P3 RNA expression.
This table summarizes NDUFS5P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NDUFS5P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFS5P3 shows lower tumor expression in COAD and higher tumor expression in KIRC, LUAD and LUSC. The KIRC box plot shows higher NDUFS5P3 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .002).
This table shows molecular features associated with NDUFS5P3 in patient tissues and cancer cell lines. In patient samples, NDUFS5P3 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
